Jim Simons Arcus Biosciences, Inc. Transaction History

Renaissance Technologies LLC

$56.7 Billion
Q2 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 82,400 shares of RCUS stock, worth $1.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,400

Previous 240,500 65.74%

Holding current value

$1.27 Million

Previous $4.54 Million 72.38%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$14.59 - $18.48 $2.31 Million - $2.92 Million	-158,100 Reduced 65.74%	82,400 $1.25 Million
Q1 2024 May 13, 2024	BUY	$14.83 - $20.18 $1.74 Million - $2.36 Million	117,000 Added 94.74%	240,500 $4.54 Million
Q4 2023 Feb 13, 2024	SELL	$13.43 - $19.63 $259,199 - $378,859	-19,300 Reduced 13.52%	123,500 $2.36 Million
Q3 2023 Nov 14, 2023	BUY	$17.62 - $23.54 $2.52 Million - $3.36 Million	142,800 New	142,800 $2.56 Million
Q3 2021 Nov 12, 2021	SELL	$26.93 - $37.68 $7.42 Million - $10.4 Million	-275,700 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$22.75 - $35.77 $427,700 - $672,476	18,800 Added 7.32%	275,700 $7.57 Million
Q1 2021 May 13, 2021	BUY	$26.16 - $41.39 $6.72 Million - $10.6 Million	256,900 New	256,900 $7.21 Million
Q2 2020 Aug 13, 2020	SELL	$13.97 - $36.56 $3.65 Million - $9.56 Million	-261,416 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$8.78 - $19.28 $387,882 - $851,751	44,178 Added 20.34%	261,416 $3.63 Million
Q4 2019 Feb 13, 2020	BUY	$7.33 - $10.79 $560,012 - $824,355	76,400 Added 54.25%	217,238 $2.19 Million
Q3 2019 Nov 13, 2019	BUY	$6.44 - $10.18 $684,172 - $1.08 Million	106,238 Added 307.05%	140,838 $1.28 Million
Q2 2019 Aug 12, 2019	BUY	$7.29 - $13.38 $252,234 - $462,948	34,600 New	34,600 $275,000

Others Institutions Holding RCUS

# of Institutions

207

Shares Held

49M

Call Options Held

173K

Put Options Held

151K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.11B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account